Theranostic approach to transplant rejection using engineered cell biosensors

Project Details


Abstract Liver transplants are a life-saving treatment for patients, but have slow and insensitive metrics of transplant rejection. This application explores a genetically engineered cell biosensor that is pre- engrafted into a transplant in order to report and respond to early warning signals of transplant failure through the following aims: (1) In Vitro Screening of MSC Biosensors Against Plasma from Transplant Recipients, and (2) Theranostic Study Of Ex Vivo Engrafted Biosensors in Allograft Rejection Settings. These data will establish a proof-of-concept of cell biosensors for to monitor and locally treat transplanted organs with impact in basic and applied transplant biology research.
Effective start/end date5/14/184/30/21


  • National Institute of Allergy and Infectious Diseases: $252,750.00
  • National Institute of Allergy and Infectious Diseases: $210,625.00


  • Transplantation
  • Biotechnology


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.